Pharmacoeconomic Evaluation of Clinical Pharmacology Service Efficiency in Terms of Outpatient Drug Supply in Nur-Sultan Medical Organization (Kazakhstan)
IF 0.5 4区 医学Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
D. Utepova, R. Magzumova, D. Baidullayeva, M. Aljofan
{"title":"Pharmacoeconomic Evaluation of Clinical Pharmacology Service Efficiency in Terms of Outpatient Drug Supply in Nur-Sultan Medical Organization (Kazakhstan)","authors":"D. Utepova, R. Magzumova, D. Baidullayeva, M. Aljofan","doi":"10.32921/2225-9929-2021-4-44-50-61","DOIUrl":null,"url":null,"abstract":"Purpose of the study. Evaluate the clinical pharmacologist's contribution to the rational use of medications at the outpatient level.Methods. Clinical and economic analysis of budgetary expenditures on drugs purchased as part of the Guaranteed amount of free medical care and in the system of mandatory social health insurance (MSHI) for the period from 2019-2021. Assessment of the effectiveness of spending budgetary funds for drugs was conducted using data on the number and cost of drugs purchased to provide outpatient care in the medical organization of Nur-Sultan.Results. A three-year analysis showed a positive trend of a 7.1% decrease in the proportion of spending on unproven drugs (index N) by 2021 compared with the previous year 2020, which was 29.54% of spending on 13 drug items, despite the expansion of lists under insurance medicine. Before the introduction of mandatory social health insurance in 2019, this figure was 8.18% of all outpatient drug coverage costs in the Guaranteed amount of free medical care, indicating an average use of drugs not included in international clinical guidelines.Conclusions. The introduction of clinical pharmacology services into clinical practice has optimized the cost of drug therapy and promoted rational use of medications. The result is a 7.1% decrease in the share of spending on unproven drugs compared to the previous year 2020, which amounted to 29.54% of spending on 13 drugs (index N) not included in the Kazakhstan National Medical Formulary and the WHO Model List of Essential Medicines. However, due to the long-term training of clinical pharmacologists, including basic education in therapeutic medicine (6-7 years) and additional education at the level of residency or doctoral studies (2-3 years), there is decreased motivation of clinical pharmacologists to work in budget medical organizations due to the \"low\" level of wages. Abroad, in particular, this problem was solved by the introduction of clinical pharmacy, where training includes basic pharmaceutical education (4-5 years) with the possibility of additional training at the master's level (1-2 years) and doctoral studies (2-3 years)","PeriodicalId":11852,"journal":{"name":"Ethiopian Journal of Health Development","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ethiopian Journal of Health Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32921/2225-9929-2021-4-44-50-61","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of the study. Evaluate the clinical pharmacologist's contribution to the rational use of medications at the outpatient level.Methods. Clinical and economic analysis of budgetary expenditures on drugs purchased as part of the Guaranteed amount of free medical care and in the system of mandatory social health insurance (MSHI) for the period from 2019-2021. Assessment of the effectiveness of spending budgetary funds for drugs was conducted using data on the number and cost of drugs purchased to provide outpatient care in the medical organization of Nur-Sultan.Results. A three-year analysis showed a positive trend of a 7.1% decrease in the proportion of spending on unproven drugs (index N) by 2021 compared with the previous year 2020, which was 29.54% of spending on 13 drug items, despite the expansion of lists under insurance medicine. Before the introduction of mandatory social health insurance in 2019, this figure was 8.18% of all outpatient drug coverage costs in the Guaranteed amount of free medical care, indicating an average use of drugs not included in international clinical guidelines.Conclusions. The introduction of clinical pharmacology services into clinical practice has optimized the cost of drug therapy and promoted rational use of medications. The result is a 7.1% decrease in the share of spending on unproven drugs compared to the previous year 2020, which amounted to 29.54% of spending on 13 drugs (index N) not included in the Kazakhstan National Medical Formulary and the WHO Model List of Essential Medicines. However, due to the long-term training of clinical pharmacologists, including basic education in therapeutic medicine (6-7 years) and additional education at the level of residency or doctoral studies (2-3 years), there is decreased motivation of clinical pharmacologists to work in budget medical organizations due to the "low" level of wages. Abroad, in particular, this problem was solved by the introduction of clinical pharmacy, where training includes basic pharmaceutical education (4-5 years) with the possibility of additional training at the master's level (1-2 years) and doctoral studies (2-3 years)
期刊介绍:
The Ethiopian Journal of Health Development is a multi and interdisciplinary platform that provides space for public health experts in academics, policy and programs to share empirical evidence to contribute to health development agenda.
We publish original research articles, reviews, brief communications and commentaries on public health issues, to inform current research, policy and practice in all areas of common interest to the scholars in the field of public health, social sciences and humanities, health practitioners and policy makers. The journal publishes material relevant to any aspect of public health from a wide range of fields: epidemiology, environmental health, health economics, reproductive health, behavioral sciences, nutrition, psychiatry, social pharmacy, medical anthropology, medical sociology, clinical psychology and wide arrays of social sciences and humanities.
The journal publishes the following types of contribution:
1) Peer-reviewed original research articles and critical or analytical reviews in any area of social public health. These papers may be up to 3,500 words excluding abstract, tables, and references. Papers below this limit are preferred.
2) Peer-reviewed short reports of research findings on topical issues or published articles of between 2000 and 4000 words.
3) Brief communications, and commentaries debating on particular areas of focus, and published alongside, selected articles.
4) Special Issues bringing together collections of papers on a particular theme, and usually guest edited.
5) Editorial that flags critical issues of public health debate for policy, program and scientific consumption or further debate